Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 198

1.

Correction to: Imaging and Genetic Approaches to Inform Biomarkers for Anxiety Disorders, Obsessive-Compulsive Disorders, and PSTD.

Maron E, Lan CC, Nutt D.

Curr Top Behav Neurosci. 2018 Oct 24. doi: 10.1007/7854_2018_64. [Epub ahead of print]

PMID:
30488349
2.

Predicting Responses to Psychedelics: A Prospective Study.

Haijen ECHM, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, Nutt D, Daws RE, Hampshire ADG, Lorenz R, Carhart-Harris RL.

Front Pharmacol. 2018 Nov 2;9:897. doi: 10.3389/fphar.2018.00897. eCollection 2018.

3.

THuNDRous news for human dopamine researchers: A selective dopamine D1 receptor antagonist will soon be available for clinical research.

Nutt D, Robbins T, Hayes A.

J Psychopharmacol. 2018 Nov;32(11):1153-1154. doi: 10.1177/0269881118799380. Epub 2018 Oct 24. No abstract available.

PMID:
30354927
4.

DMT Models the Near-Death Experience.

Timmermann C, Roseman L, Williams L, Erritzoe D, Martial C, Cassol H, Laureys S, Nutt D, Carhart-Harris R.

Front Psychol. 2018 Aug 15;9:1424. doi: 10.3389/fpsyg.2018.01424. eCollection 2018.

5.

Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level.

van den Brink W, Addolorato G, Aubin HJ, Benyamina A, Caputo F, Dematteis M, Gual A, Lesch OM, Mann K, Maremmani I, Nutt D, Paille F, Perney P, Rehm J, Reynaud M, Simon N, Söderpalm B, Sommer WH, Walter H, Spanagel R.

Addict Biol. 2018 Jul;23(4):969-986. doi: 10.1111/adb.12645.

PMID:
30043457
6.

Cannabis and opioid overdoses: time to move on and examine potential mechanisms.

Rogeberg O, Blomkvist AW, Nutt D.

Addiction. 2018 Aug;113(8):1551-1552. doi: 10.1111/add.14238. Epub 2018 Jun 7. No abstract available.

PMID:
29882246
7.

Towards earlier diagnosis and treatment of disorders of the brain.

Di Luca M, Nutt D, Oertel W, Boyer P, Jaarsma J, Destrebecq F, Esposito G, Quoidbach V.

Bull World Health Organ. 2018 May 1;96(5):298-298A. doi: 10.2471/BLT.17.206599. No abstract available.

8.

Imaging and Genetic Approaches to Inform Biomarkers for Anxiety Disorders, Obsessive-Compulsive Disorders, and PSTD.

Maron E, Lan CC, Nutt D.

Curr Top Behav Neurosci. 2018 May 24. doi: 10.1007/7854_2018_49. [Epub ahead of print]

PMID:
29796838
9.

Correction to: The hidden therapist: evidence for a central role of music in psychedelic therapy.

Kaelen M, Giribaldi B, Raine J, Evans L, Timmermann C, Rodriguez N, Roseman L, Feilding A, Nutt D, Carhart-Harris R.

Psychopharmacology (Berl). 2018 May;235(5):1623. doi: 10.1007/s00213-018-4886-8.

10.

A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation.

Rogeberg O, Bergsvik D, Phillips LD, van Amsterdam J, Eastwood N, Henderson G, Lynskey M, Measham F, Ponton R, Rolles S, Schlag AK, Taylor P, Nutt D.

Int J Drug Policy. 2018 Jun;56:144-152. doi: 10.1016/j.drugpo.2018.01.019. Epub 2018 Feb 17.

11.

Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation.

Curran HV, Nutt D, de Wit H.

Psychopharmacology (Berl). 2018 Feb;235(2):373-375. doi: 10.1007/s00213-017-4822-3. No abstract available.

PMID:
29445838
12.

The hidden therapist: evidence for a central role of music in psychedelic therapy.

Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, Roseman L, Feilding A, Nutt D, Carhart-Harris R.

Psychopharmacology (Berl). 2018 Feb;235(2):505-519. doi: 10.1007/s00213-017-4820-5. Epub 2018 Feb 2. Erratum in: Psychopharmacology (Berl). 2018 Mar 26;:.

13.

A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability.

Davies B, Brown LA, Cais O, Watson J, Clayton AJ, Chang VT, Biggs D, Preece C, Hernandez-Pliego P, Krohn J, Bhomra A, Twigg SRF, Rimmer A, Kanapin A; WGS500 Consortium, Sen A, Zaiwalla Z, McVean G, Foster R, Donnelly P, Taylor JC, Blair E, Nutt D, Aricescu AR, Greger IH, Peirson SN, Flint J, Martin HC.

Hum Mol Genet. 2017 Oct 15;26(20):3869-3882. doi: 10.1093/hmg/ddx270.

14.

Is the UK's 2017 drug strategy fit for purpose?

Ford C, Nutt D, Eastwood N, Gold D, Jolly J, Murphy F, Halliday K, Bridge J.

BMJ. 2017 Sep 29;358:j4405. doi: 10.1136/bmj.j4405. No abstract available.

PMID:
28963111
15.

Biological markers of generalized anxiety disorder.

Maron E, Nutt D.

Dialogues Clin Neurosci. 2017 Jun;19(2):147-158. Review.

16.

A Brief Outline of the Use of New Technologies for Treating Substance Use Disorders in the European Union.

Quaglio G, Schellekens A, Blankers M, Hoch E, Karapiperis T, Esposito G, Brand H, Nutt D, Kiefer F.

Eur Addict Res. 2017;23(4):177-181. doi: 10.1159/000478904. Epub 2017 Aug 12.

PMID:
28803249
17.

New ACMD regulations threaten UK's pharmaceutical discovery.

Nutt D.

Lancet. 2017 Jun 10;389(10086):2283. doi: 10.1016/S0140-6736(17)31461-7. No abstract available.

PMID:
28612742
18.

A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial.

Masters A, Nutt D.

J Med Ethics. 2017 Nov;43(11):730-736. doi: 10.1136/medethics-2016-104050. Epub 2017 Jun 6.

19.

Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.

Singh I, Morgan C, Curran V, Nutt D, Schlag A, McShane R.

Lancet Psychiatry. 2017 May;4(5):419-426. doi: 10.1016/S2215-0366(17)30102-5. Epub 2017 Apr 5. Review.

PMID:
28395988
20.

Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.

Quelch DR, Mick I, McGonigle J, Ramos AC, Flechais RSA, Bolstridge M, Rabiner E, Wall MB, Newbould RD, Steiniger-Brach B, van den Berg F, Boyce M, Østergaard Nilausen D, Breuning Sluth L, Meulien D, von der Goltz C, Nutt D, Lingford-Hughes A.

Biol Psychiatry. 2017 Jun 1;81(11):941-948. doi: 10.1016/j.biopsych.2016.12.029. Epub 2017 Jan 10.

Supplemental Content

Loading ...
Support Center